Drug Price Trends for HM ASPIRIN EC

Average Pharmacy Cost for HM ASPIRIN EC

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HM ASPIRIN EC 81 MG TABLET	62011-0019-01	0.01491	EACH	2025-12-17
HM ASPIRIN EC 81 MG TABLET	62011-0019-01	0.01481	EACH	2025-11-19
HM ASPIRIN EC 81 MG TABLET	62011-0019-01	0.01492	EACH	2025-10-22
HM ASPIRIN EC 81 MG TABLET	62011-0019-01	0.01441	EACH	2025-09-17
HM ASPIRIN EC 81 MG TABLET	62011-0019-01	0.01443	EACH	2025-08-20
HM ASPIRIN EC 81 MG TABLET	62011-0019-01	0.01440	EACH	2025-07-23

HM ASPIRIN EC Market Analysis and Financial Projection

Last updated: February 14, 2026

What is HM Aspirin EC?

HM Aspirin EC is a brand of enteric-coated aspirin primarily used as an analgesic, antipyretic, and antiplatelet agent. Enteric coating helps prevent gastric irritation by delaying aspirin absorption until it reaches the intestines. The drug is typically marketed in 81 mg (low-dose) and 325 mg (standard dose) formulations.

What is the current market presence of HM Aspirin EC?

As a generic or branded formulation, HM Aspirin EC is sold across multiple regions, including North America, Europe, and parts of Asia. It is often available via OTC channels and hospital formulary. Major pharmaceutical companies manufacture versions adhering to regulatory standards such as FDA approval in the U.S. and EMA in Europe.

How does the market for aspirin products look?

• The global aspirin market was valued at approximately $2.5 billion in 2022.
• CAGR (compound annual growth rate) estimated at 3.2% from 2023 to 2030.
• The increasing prevalence of cardiovascular conditions fuels demand for low-dose aspirin as an antiplatelet therapy.
• OTC sales account for roughly 60% of total sales, driven by self-medication trends.
• Prescription segment also growing, especially for secondary prevention of cardiovascular events.

What are the key competitors in the aspirin market?

Brand/Product	Dosages	Market Share (2022)	Notable Features
Bayer Aspirin	81 mg, 325 mg	40%	Largest global brand, OTC-heavy
St. Joseph Aspirin	81 mg, 325 mg	15%	Popular in North America
Ecotrin (Bayer)	81 mg	10%	Enteric-coated, non-acetylated
Generic Aspirin (various)	81 mg, 325 mg	25%	Price-competitive, widespread use
Others	Variable	10%	Niche markets, regional brands

What are the regulatory and patent considerations?

• Patent status for HM Aspirin EC holds in key markets varies; patents generally expired by early 2010s, allowing generics.
• Regulatory approval depends on local agencies, but the drug generally complies with standard GMP (Good Manufacturing Practice) and safety data.
• Market entry of generics intensifies competition but also expands access.

What are the price trends and projections?

Recent pricing trends (U.S. OTC market):

Year	Average Retail Price per 100 tablets	Key Notes
2020	$4.50	Price stability across brands
2021	$4.75	Slight increase amid supply chain disruptions
2022	$4.80	Market stabilization

Projected price trajectory (2023–2030):

• Prices are expected to grow at roughly 1.5% annually due to inflation, manufacturing costs, and competitive pressures.
• The entry of premium formulations or innovations in delivery could influence pricing; however, the core low-dose aspirin market remains price-sensitive.

What are the factors influencing price and market growth?

• Increased awareness of cardiovascular disease management maintains high demand.
• Growing consumer preference for OTC analgesics supports retail sales.
• Development of combination therapies may reduce standalone aspirin sales, affecting pricing.
• Regulatory environment and patent litigation influence market stability.
• Supply chain issues, including raw material sourcing, can impact manufacturing costs and pricing.

What is the outlook for HM Aspirin EC?

• Market size: Expected to sustain at approximately $2.5 billion globally, with moderate growth driven by aging populations.
• Price: Stabilize around current levels, with slight annual increases.
• Competitive landscape: Expected increase in generics, pressuring pricing.
• Innovation: Limited, with aspirin use largely unchanged; however, new formulations or combination products could shift dynamics.

Key Takeaways

• HM Aspirin EC faces a mature, highly competitive market dominated by generics.
• Pricing remains steady with modest growth prospects.
• Market growth driven primarily by demographic trends and cardiovascular health awareness.
• Price reductions may occur as generics expand market share.
• Opportunities may exist in combination therapies or new delivery mechanisms, though aspirin's low-cost profile limits high-margin innovations.

FAQs

1. How does the enteric coating impact pricing?

Enteric-coated aspirin competes mainly on formulation benefits rather than price; it typically commands a slight premium over non-coated equivalents due to perceived gastrointestinal safety.

2. Will patent expirations affect HM Aspirin EC?

Existing patents for aspirin formulations have largely expired, facilitating generic competition that pressures prices downward.

3. Are new regulations expected to influence the market?

Regulations for OTC drugs like aspirin focus on safety standards; recent updates have not significantly altered market dynamics but may increase compliance costs.

4. What demographic factors influence demand?

Ageing populations and increased awareness of cardiovascular health sustain steady demand, especially among individuals over 50.

5. How do supply chain issues impact prices?

Disruptions in raw material sourcing or manufacturing capacity can lead to supply shortages, temporarily increasing prices or reducing availability.

Sources:

1. MarketWatch. "Global Aspirin Market size, share and growth analysis." 2022.
2. Mordor Intelligence. "Aspirin Market - Growth, Trends, and Forecast (2023–2030)."
3. U.S. Food and Drug Administration (FDA). "OTC Aspirin Monograph."
4. IQVIA. "OTC Analgesics Market Data," 2022.
5. Statista. "Global Aspirin Market Revenue Forecast," 2023.